title: Site-dependent differences in response of the UV-2237 murine fibrosarcoma to systemic therapy with adriamycin.
abstract: Murine fibrosarcoma UV-2237MM cells were implanted into different organs of syngeneic C3H/HeN mice. The resultant tumors were treated by i.v. administration of Adriamycin (ADR). Despite the high sensitivity of the fibrosarcoma cells to ADR in vitro, the established tumors growing in vivo exhibited marked differences in their responses to ADR. Tumors growing in the subcutis and the spleen were ADR-sensitive, whereas lung metastases were not. The resistance of lung metastases to ADR was not due to selection of a drug-resistant population since tumor cells isolated from lung metastases were highly sensitive to ADR under in vitro conditions. The responsiveness of skin and spleen tumors to ADR was due neither to increased blood supply nor to preferential accumulation of ADR, since both parameters were higher in lung metastases. Protein kinase C activity levels correlated with ADR resistance in the closely related murine fibrosarcoma cell line UV-2237 and its ADR-selected multidrug-resistant variants. However, nearly identical levels of protein kinase C activity were found in UV-2237MM tumors growing in the lung, spleen, and subcutis, indicating that protein kinase C activity levels did not account for the different responses to ADR. The present studies suggest that the organ environment influences the response of UV-2237MM to ADR administered systemically. This finding may have implications for the design of animal models for therapy of disseminated cancer.
authors: Department of Cell Biology, University of Texas M.D. Anderson Cancer Center, Houston 77030.
authors: A N
authors: AN
authors: Staroselsky
authors: D
authors: D
authors: Fan
authors: C A
authors: CA
authors: O'Brian
authors: C D
authors: CD
authors: Bucana
authors: K P
authors: KP
authors: Gupta
authors: I J
authors: IJ
authors: Fidler
mesh_terms: D000818:Animals; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D004317:Doxorubicin / Q000494:pharmacology*; D005260:Female; D005354:Fibrosarcoma / Q000188:drug therapy* / Q000473:pathology; D008175:Lung Neoplasms / Q000473:pathology / Q000556:secondary; D051379:Mice; D008809:Mice, Inbred C3H; D009368:Neoplasm Transplantation; D009928:Organ Specificity
chemical_list: D004317:Doxorubicin